DGCR2 Antibody (1019908) [Alexa Fluor® 750]

• Reactivity: Hu, Mu, Rt
• Applications: WB
• Clone: 1019908
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor 750

DGCR2 Antibody (1019908) [Alexa Fluor® 750] Summary

• Immunogen: Chinese Hamster Ovary cell line CHO-derived human DGCR2
  Glu22-Ala349
  Accession # P98153
• Specificity: Detects human, mouse, and rat DGCR2 in Western blots. Detects human DGCR2 in direct ELISAs.
• Isotype: IgG2b
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified

Applications/Dilutions

• Dilutions:
  • Western Blot

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for DGCR2 Antibody (1019908) [Alexa Fluor® 750]

• DGCR2
• DGS-C
• DiGeorge syndrome critical region gene 2
• IDDDKFZp686I1730
• integral membrane protein deleted in DiGeorge syndrome
• integral membrane protein DGCR2/IDD
• KIAA0163
• KIAA0163DiGeorge syndrome critical region protein 2
• LAN
• SEZ-12

Background

DiGeorge Syndrome Critical Region 2 (DGCR2), also known as IDD, DGS-C, LAN, and SEZ-12, is an adhesion receptor protein located on the long arm of chromosome 22 (1). The DGCR2 gene encodes an integral membrane protein, consisting of an extracellular domain, a single transmembrane region and a cytoplasmic tail (1). The mature extracellular domain (ECD) of DGCR2 contains both a C-type lectin domain and a cysteine-rich region similar to that of the low density lipoprotein receptor (LDLR) (1, 3). The mature ECD of human DGCR2 shares 93% and 92% amino acid sequence identity with mouse and rat, respectively. DGCR2 is expressed during neurodevelopment in human brain tissues (3). Deletion of the 22q11.2 region results in an extremely variable disorder called 22q11.2 deletion syndrome, with a phenotype ranging from very mild symptoms to severe intellectual disability, facial dysmorphism, heart defects, and urogenital abnormalities (4). Recent studies suggest that DGCR2 regulates critical steps of early cortico-genesis possibly through a Reelin-dependent mechanism. Deletion of DGCR2 has a pathogenic impact on cortical formation by reducing protein expression level, and it plays a critical role in vulnerability to schizophrenia (5). Furthermore, expression of DGCR2 together with USP18 gene may serve as a progonostic marker for muscle invasive bladder cancer survival in patients (5).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.